Combination therapy for recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of a drug called GEP (likely gemcitabine, cisplatin, and a PD-1 inhibitor) with radiation therapy for people whose nasopharyngeal cancer has returned and cannot be treated with standard local treatments. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- Your cancer has come back in the nose/throat area and is not suitable for curaitve local treatment like surgery or radiation
- You are able to perform daily activities with some help (ECOG 0-2)
- You have acceptable blood counts, liver, kidney, and heart function
- You must be willing to sign a consent form and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of two drugs—an investigational antibody that targets cancer cells (MRG003) and a chemotherapy pill (capecitabine)—along with an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back but hasn't spread. The goal is to see if this approach can help control the cancer.
This study tests a new combination for people whose nasopharyngeal cancer has returned in the same area and cannot be removed by surgery. The treatment combines a targeted drug (becotatug vedotin), an immunotherapy (PD-1 antibody), and radiation to try to shrink or control the cancer.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation can help people whose nasopharyngeal cancer has spread to the lungs or chest area. The treatment aims to shrink tumors and may improve outcomes for patients in this situation.
Hear when a new Nasopharynx Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.